Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other financing activities (2018 - 2022)

Zevra Therapeutics (ZVRA) has disclosed Other financing activities for 6 consecutive years, with -$68000.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Other financing activities fell 104.3% year-over-year to -$68000.0, compared with a TTM value of -$68000.0 through Sep 2024, changed N/A, and an annual FY2024 reading of $2.1 million, changed N/A over the prior year.
  • Other financing activities was -$68000.0 for Q4 2022 at Zevra Therapeutics, down from $68000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $2.9 million in Q1 2021 and bottomed at -$1.6 million in Q3 2021.
  • Average Other financing activities over 4 years is $206111.1, with a median of $34000.0 recorded in 2020.
  • The sharpest move saw Other financing activities surged 8373.53% in 2021, then tumbled 104.3% in 2022.
  • Year by year, Other financing activities stood at -$1.1 million in 2018, then soared by 94.06% to -$63000.0 in 2020, then soared by 2611.11% to $1.6 million in 2021, then tumbled by 104.3% to -$68000.0 in 2022.
  • Business Quant data shows Other financing activities for ZVRA at -$68000.0 in Q4 2022, $68000.0 in Q2 2022, and $1.6 million in Q4 2021.